Antibiotic Prescribing in DR Congo: A Knowledge, Attitude and Practice Survey among Medical Doctors and Students

Thriemer, Kamala; Katuala, Yves; Batoko, Bibi; Alworonga, Jean-Pierre; Devlieger, Hugo; Van Geet, Christel; Ngbonda, Dauly; Jacobs, Jan
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Objectives: Antibiotic resistance (ABR) particularly hits resource poor countries, and is fuelled by irrational antibiotic (AB) prescribing. We surveyed knowledge, attitudes and practices of AB prescribing among medical students and doctors in Kisangani, DR Congo. Methods: Self-administered questionnaires. Results: A total of 184 questionnaires were completed (response rate 94.4%). Knowledge about AB was low (mean score 4.9/8 points), as was the estimation of local resistance rates of S. Typhi and Klebsiella spp.(correct by 42.5% and 6.9% of respondents respectively). ABR was recognized as a problem though less in their own practice (67.4%) than nation- or worldwide (92.9% and 85.5%, p<.0001). Confidence in AB prescribing was high (88.6%) and students consulted more frequently colleagues than medical doctors when prescribing (25.4% versus 11.6%, p  = 0.19). Sources of AB prescribing included pharmaceutical companies (73.9%), antibiotic guidelines (66.3%), university courses (63.6%), internet-sites (45.7%) and WHO guidelines (26.6%). Only 30.4% and 16.3% respondents perceived AB procured through the central procurement and local pharmacies as of good quality. Local AB guidelines and courses about AB prescribing are welcomed (73.4% and 98.8% respectively). Conclusions: This data shows the need for interventions that support rational AB prescribing.


Related Articles

  • Bayer's Bacteria. Mokhiber, Russell // Multinational Monitor;Apr2001, Vol. 22 Issue 4, p29 

    Reports that public interest groups called on the Bayer Corp. to end its opposition to the proposed ban on the use of fluoroquinolones antibiotic in the United States. Challenges and arguments posed by Bayer against the proposed ban; Role of fluoroquinolones in antibiotic resistance; Factors...

  • ODs can help reduce antibiotic resistance. DePaolis, Michael D. // Primary Care Optometry News;Sep2013, Vol. 18 Issue 9, p3 

    The article discusses the challenge of antibiotic resistance for several pharmaceutical companies.

  • The post-antibiotic era beckons. Fox, Robin // Journal of the Royal Society of Medicine;Nov1996, Vol. 89 Issue 11, p602 

    The article examines Stuart Levy's antibiotic paradox, which is the fact that miracle drugs tend to lose their power because of antibiotic misuse resulting in drug resistance in microorganisms. Levy's warning had previously not been heeded even by doctors. However, multiresistant microorganisms...

  • Herramientas para rastrear la resistencia a los antibióticos. Lubick, Naomi // Salud Pública de México;mayjun2011, Vol. 53 Issue 3, p270 

    No abstract available.

  • Pharma Leads Potential $750M Effort to Advance Antibiotics. Moran, Nuala // BioWorld International;5/30/2012, p1 

    The article focuses on "New Drugs for Bad Drugs," a cooperative effort in Europe to address the growing antibiotic resistance. A Phase IIa compound will be advanced by GlaxoSmithKline PLC in clinical development as part of the public-private program. AstraZeneca PLC has two clinical-stage...

  • Chief scientist calls for action on antibiotic resistance.  // Australian Journal of Pharmacy;Sep2013, Vol. 94 Issue 1120, p6 

    The article focuses on the "Meeting the threat of antibiotic resistance: Building a new frontline defence" paper from the Office of the Chief Scientist in Australia which addresses the increasing threat of antibiotic resistance. Topics include the scale of the threat and consequences of...

  • Sources of novel antibiotics-aside the common roads. Donadio, Stefano; Maffioli, Sonia; Monciardini, Paolo; Sosio, Margherita; Jabes, Daniela // Applied Microbiology & Biotechnology;Nov2010, Vol. 88 Issue 6, p1261 

    Microbial pathogens are becoming increasingly resistant to available treatments, and new antibiotics are badly needed, but the pipeline of compounds under development is scarce. Furthermore, the majority of antibiotics under development are improved derivatives of marketed compounds, which are...

  • Financings roundup.  // Medical Device Daily;4/19/2013, Vol. 17 Issue 74, p3 

    The article reports that biopharmaceutical company, Allecra Therapeutics received a Series A financing scheme of 15 million euros from Edmond de Rothschild Investment Partners and Forbion Capital Partners.

  • Europe addresses antibiotic resistance. Jessop, Nathan // Pharmaceutical Technology Europe;Dec2010, Vol. 22 Issue 12, p12 

    The article offers information on the national public education campaigns regarding antibiotic resistance in Europe. It mentions the role of the European Antibiotic Awareness Day initiative that is designed to strengthen Europe's defences against infectious diseases. It notes that pharmaceutical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics